Fig. 1From: Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1Eliglustat exposure by dose regimen. Panel a shows the percent of patients on each dose regimen and Panel b shows the proportion of total exposure in patient-yearsBack to article page